We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Blood Test Determines Irritable Bowel Syndrome

By LabMedica International staff writers
Posted on 21 Nov 2013
Print article
Image: Micrograph of cryptitis in a case of Inflammatory Bowel Disease from a colonic biopsy of the mucosa (Photo courtesy of Nephron).
Image: Micrograph of cryptitis in a case of Inflammatory Bowel Disease from a colonic biopsy of the mucosa (Photo courtesy of Nephron).
A blood test could easily determine whether a patient is suffering from Irritable Bowel Syndrome (IBS), eliminating the need for extensive and expensive dialogistic testing in order to rule out more serious conditions like Inflammatory Bowel Disease (IBD).

Vinculin is a cell migration and adherence protein found predominantly on nerves and epithelium and a series of studies suggests that acute gastroenteritis causes antibodies to be formed to vinculin and is associated with IBS development.

Scientists at the Cedars Sinai Medical Center (Los Angeles, CA, USA) evaluated 165 IBS, 30 IBD and 26 healthy control subjects and demographics were similar between groups. The IBS subjects were aged between 18 and 65 and were all positive according to the Rome criteria. Subjects with IBD were recruited from an expert tertiary care medical center.

Overall, IBS had a significantly greater optical density in the enzyme-linked immunoassay (ELISA) for anti-vinculin antibodies compared to IBD and healthy subjects. The results from Cedars Sinai Medical Center were compared to those at Beth Israel Deaconess Medical Center (Boston, MA, USA) for IBS recruitment, and the findings from both centers were similarly abnormal. Interestingly, subjects with a history of acute gastroenteritis, even higher levels of antibodies were seen.

Mark Pimentel, MD, the lead author of this multicenter study, said, “Anti-vinculin antibodies are elevated in IBS compared to non-IBS. This is the first diagnostic test for IBS based on serum and a pathophysiologic mechanism of IBS through acute gastroenteritis precipitating molecular mimicry and autoimmunity. This is a major breakthrough as the first test to potentially distinguish IBS from IBD and reduce the need for unnecessary testing in these conditions. Moreover, this test is based on a potential pathophysiologic mechanism of IBS development.”

In the USA, it is estimated that 10%–15% of the adult population suffers from IBS symptoms, yet only 5%–7% of adults have been diagnosed with the disease. IBS is the most common disease diagnosed by gastroenterologists and one of the most common disorders seen by primary care physicians. The study was presented at 78th Annual Scientific Meeting of the American College of Gastroenterology, held October 11-16, 2013, in San Diego (CA, USA).

Related Links:

Cedars Sinai Medical Center
Beth Israel Deaconess Medical Center 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
Centrifuge
Hematocrit Centrifuge 7511M4

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.